+44 (0) 20 7549 9987 | USA callers: 00-1-718-682-4567

Contact Us Now

Market for psoriasis drugs will reach $11.4bn in 2020, according to new visiongain data

05 September 2018
Pharma

The updated study analyses events, prospects and sales opportunities shaping the development, production and marketing of drugs for the treatment of psoriasis. The analysis shows multilevel revenue forecasting and qualitative assessments. The work also explores activities of leading companies providing those medicines, assessing their potentials from 2016.

In 2015 biological drugs formed dominant source of revenue for manufacturers, accounting for 78.5% of the global drug market for psoriasis. However that segment will decline in market share over the forecast period as leading products such as AbbVie’s Humira (adalimumab), Amgen/Pfizer’s Enbrel (etanercept) and J&J/Merck’s Remicade (infliximab) face strong competition from lower-cost biosimilars and new biologics.

Alastair McDougall, a pharmaceutical industry analyst in visiongain, said: “The psoriasis drugs market is dynamic, with a lot of new products reaching the marketplace in the next few years. Many of the current biologics are coming off-patent, new biologics with novel mechanisms of action are being launched, and a lot of companies are actively developing biosimilars. Competition in the biologics sector will be fierce, and efficacy, safety and price will all be key considerations when evaluating products.”

Visiongain’s investigation shows revenue predictions at overall world market, submarket, product and national level. The report’s overarching analysis gives revenue forecasts to 2026 for three submarkets at world level:

• Biologics
• Systemic small molecule treatments
• Topical therapies.

The study also forecasts revenues of established brands and medicines expected from 2016. That work assesses 13 drugs to 2026, including these brands:

• Humira (adalimumab)
• Enbrel (etanercept)
• Remicade (infliximab)
• Stelara (ustekinumab)
• Otezla (apremilast)
• Cosentyx (secukinumab).

The analysis also covers prominent national markets for psoriasis drug sales, with revenue forecasts to 2026 for these 11 countries:

• USA
• Japan
• Germany, France, Italy, Spain and UK (the EU5 group)
• Brazil, Russia, India and China (BRIC countries).

Visiongain’s survey examines leading pharmaceutical companies in that market. That work discusses mergers and acquisitions, collaborations and R&D for organisations including AbbVie, Amgen, Johnson & Johnson, Pfizer, Celgene, LEO Pharma and Novartis.

Psoriasis Drugs Market Forecasts 2016-2026 adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, medical devices, diagnostics and outsourced services.

Recent News

Visiongain Publishes Gene Amplification Technologies Market Report 2023-2033

The Gene Amplification Technologies market was valued at US$4,587 million in 2022 and is projected to grow at a CAGR of 9.8% during the forecast period 2023-2033.

05 December 2022

Read

Visiongain Publishes Stem Cell Technologies and Applications Market Report 2022-2032

The global stem cell technologies and applications market was valued at US$9,247 million in 2021 and is projected to grow at a CAGR of 8.9% during the forecast period 2022-2032.

01 December 2022

Read

Visiongain Publishes Biosimilars and Follow-On Biologics Market Report 2023-2033

The biosimilars and follow-on biologics market is valued at US$19,668.3 million in 2022 and is projected to grow at a CAGR of 31.14% during the forecast period 2023-2033.

01 December 2022

Read

Visiongain Publishes Medical Imaging Market Report 2022-2032

The Medical Imaging market was valued at US$38.6 billion in 2021 and is projected to grow at a CAGR of 5.46% during the forecast period 2022-2032.

30 November 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever